| Main mechanisms of action | Candidate drugs | Stage of development in trails |
| Acetylcholinesterase inhibitors Specific IP3R antagonist β-secretase inhibitors Active immunotherapy that increase Aβ clearance Passive immunotherapy that increase Aβ clearance Non-specific GSK3 inhibitor Anti-tau that decrease tau fibrillization MT-stabilizing products | Huperzine A ULMWH Rosiglitazone Pioglitazone AN1792 and CAD-106 AAB-001 and LY2062430 Lithium salt Methylene blue Paclitaxel Epothilone D | RCTs completed [10] Vitro experiments [47] RCTs completed [48] Phase 2 RCT in MCI [48] RCTs completed [53] RCTs completed [54] Vitro animal model [55] Phase 1b clinical trail [46] |